Abstract

An enzyme mixture (EM) of glucose oxidase, glucosyl transferase, and fructosyl transferase can regulate glucose absorption into the body by converting carbohydrates in food to indigestible oligosaccharides. We evaluated the antidiabetic effects of repeated oral administration of EM in db/db mice. Seven-week-old db/db mice were divided into control, voglibose, and EM groups. Drugs were administered orally mixed with limited feed for one month. Glucose levels were measured every week. A meal tolerance test was conducted after overnight fasting, before the mice were sacrificed. There were no differences in body weight or food intake between the groups. EM treatment reduced blood glucose levels compared with those in the control group. Blood glucose levels during the meal tolerance test were significantly lower in the EM group than those in the control group. A significant decrease in triglyceride level and a tendency for decreased low-density lipoprotein were observed in the EM group compared with in the control group. The Bacteroidetes-to-Firmicutes ratio was higher in the EM group than that in the control group. EM may be useful for people at risk of hyperglycemia or diabetes who need to safely regulate their blood glucose levels. EM may also improve lipid and gut microbiota profiles.

Highlights

  • Diabetes mellitus (DM) is a chronic metabolic disease associated with public health problems worldwide [1]

  • We evaluated the antidiabetic effects of repeated oral administration of an enzyme mixture (EM) containing glucose oxidase, glucosyl transferase, and fructosyl transferase in db/db mice

  • There was no difference in body weight in the voglibose and EM groups compared with the control group (Figure 2A)

Read more

Summary

Introduction

Diabetes mellitus (DM) is a chronic metabolic disease associated with public health problems worldwide [1]. In 2019, the prevalence of DM was. Type 2 DM (T2D), which accounts for approximately 90% of total cases, is characterized by a progressive loss of adequate β-cell insulin secretion, often in the context of insulin resistance [3]. The prevalence of T2D increases proportionally with increasing body mass index [4]. Obesity management has benefits in T2D treatment and delays the progression from prediabetes to T2D [5]. Increased physical activity and fitness combined with calorie restriction and weight loss are important in T2D treatment [6]. Metformin is used as the first-line T2D pharmacotherapy in combination with lifestyle modifications, unless there are contraindications [7]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call